You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
和黃醫藥(00013.HK):沃瑞沙和泰瑞沙聯合療法獲中國批准用於治療 觸發阿斯利康1,100萬美元里程碑付款
阿思達克 06-30 16:47
和黃醫藥(00013.HK)公布,沃瑞沙(ORPATHYS,賽沃替尼/savolitinib)和泰瑞沙(TAGRISSO,奧希替尼/osimertinib)的聯合療法的新藥上市申請獲國家藥監局批准,用於治療表皮生長因子受體(EGFR)基因突變陽性經EGFR酪氨酸激(酉每)抑制劑(TKI)治療後進展的伴MET擴增的局部晚期或轉移性非鱗狀非小細胞肺癌患者。 沃瑞沙是一種強效、高選擇性的口服MET TKI。泰瑞沙是一種不可逆的第三代EGFR TKI。此項批准將觸發一項來自阿斯利康(AZN.US)的1,100萬美元的里程碑付款,阿斯利康在中國同時負責沃瑞沙和泰瑞沙的銷售。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account